Clinical Trial Update: Assessing Clinical Outcomes in Alzheimer's Disease Agitation [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing outcomes in agitation associated with Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation in Patients with Dementia of the Alzheimer Type
• Alzheimer Disease

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Status: COMPLETED